Real‐world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: A single tertiary medical center experience in Central Taiwan-Reference-Cited by-同舟云学术

Real‐world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: A single tertiary medical center experience in Central Taiwan

Published:2020-03-12 Issue:1 Volume:8 Page:40-46
ISSN:2351-9797
Container-title:Advances in Digestive Medicine
language:en
Short-container-title:Adv in Digestive Med

Author:

Chiu Yu‐Chiao¹^ORCID,Chen Chia‐Chang¹,Ko Chung‐Wang¹,Liao Szu‐Chia¹,Yeh Hong‐Zen¹,Chang Chung‐Hsin¹

Affiliation:

1. Division of Gastroenterology and Hepatology Taichung Veterans General Hospital Taichung Taiwan

Publisher

Wiley

Subject

Gastroenterology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/aid2.13188

Reference36 articles.

1. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: A KASID study

2. Inflammatory Bowel Disease in Japan: Studies of Epidemiology and Etiopathogenesis

3. Long-term Follow-up of Ulcerative Colitis in the Chinese Population

4. Clinical Characteristics of Ulcerative Colitis in Singapore, a Multiracial City–State

5. Prevalence of ulcerative colitis and Crohn’s disease in Japan

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China;Frontiers in Pharmacology;2023-05-04

2. Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study;Inflammatory Bowel Diseases;2023-01-10

3. EXTRA-INTESTINAL MANIFESTATIONS OF CROHN DISEASE AND CHRONIC ULCERATIVE COLITIS IN THE ORAL CAVITY;Actual problems in dentistry;2022-02-04

4. Real‐World Experience of Adalimumab Therapy for Patients with Ulcerative Colitis: A Single Tertiary Medical Center Experience in Central Taiwan;Advances in Digestive Medicine;2021-10-15

5. Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study;Intestinal Research;2021-01-30